Rarer-yet-serious GLP-1 risks While rarer than the above side effects, there are some serious issues that could arise if youre taking a GLP-1
Sun YB, Zhao H, Mu DL, Zhang W, Cui J, Wu L, et al
Data published to date including results from a Phase 2 trial published in The New England Journal of Medicine in 2023 (Jastreboff et al., NEJM 2023) provide early insights into its gastrointestinal tolerability profile
206,328,329 And then, in a Phase II clinical trial, motixafortide in combination with cemiplimab and gemcitabine showed very significant results in the treatment of patients with pancreatic cancer
Increased Energy Levels: Semaglutide can help maintain stable energy levels, empowering you to stay active and engaged with your wellness goals